SLAMF7 and melanoma: Furthermore BTLA expression on CD8+ tumor-infiltrating lymphocytes was associated with improved clinical outcome in melanoma (54), aligning with our observation that SLAMF7 co-stimulation supports a less-differentiated, cytotoxic phenotype with sustained effector capacity.